Jacqueline A.M. Smith

This study shows that coexisting PTEN and PIK3CA mutations in endometrial cancers hyperactivate mTORC1, making them sensitive to mTORC1 inhibitors but not PI3K or AKT inhibitors.

This study identifies mechanisms of resistance to tri-complex RAS inhibitors in patients with RAS-driven cancers, showing that resistance alterations disrupt the RAS:drug:CYPA tri-complex formation.

This paper shows that combining RASG12C(ON) and SHP2 inhibitors can make cold lung tumors responsive to immune checkpoint blockade by altering the tumor microenvironment and enhancing anti-tumor immunity.

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.